Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 6:29 pm Sale |
2024-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
RA Capital Management, L.P. | 0 0.000% |
-6,809,404 (Position Closed) |
Filing History |
| 2025-02-05 1:23 pm Purchase |
2024-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
BLACKROCK INC BLK |
18,482,795 14.300% |
703,042 (+3.95%) |
Filing History |
| 2024-11-14 4:35 pm Purchase |
2024-09-30 | 13G | Cytek Biosciences, Inc. CTKB |
HILLHOUSE INVESTMENT MANAGEMENT LTD. | 6,657,030 5.100% |
6,657,030 (New Position) |
Filing History |
| 2024-11-14 1:42 pm Sale |
2024-09-30 | 13G | Cytek Biosciences, Inc. CTKB |
BROWN CAPITAL MANAGEMENT INC | 9,493,474 7.220% |
-2,522,851 (-21.00%) |
Filing History |
| 2024-02-22 7:07 pm Unchanged |
2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
RA Capital Management, L.P. | 6,809,404 5.200% |
0 (Unchanged) |
Filing History |
| 2024-02-14 4:39 pm Sale |
2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
HHLR Advisors, Ltd. | 6,657,030 4.900% |
-2,027,500 (-23.35%) |
Filing History |
| 2024-02-14 4:08 pm Sale |
2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
Yan Ming | 6,203,867 4.700% |
-1,999,491 (-24.37%) |
Filing History |
| 2024-02-14 4:07 pm Sale |
2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
Jiang Wenbin | 5,702,130 4.300% |
-2,318,353 (-28.91%) |
Filing History |
| 2024-02-14 3:12 pm Purchase |
2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
BROWN CAPITAL MANAGEMENT INC | 12,016,325 8.860% |
12,016,325 (New Position) |
Filing History |
| 2024-02-13 5:02 pm Purchase |
2023-12-29 | 13G | Cytek Biosciences, Inc. CTKB |
The Vanguard Group | 11,890,700 8.770% |
4,119,633 (+53.01%) |
Filing History |
| 2024-01-23 4:13 pm Purchase |
2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
BLACKROCK INC BLK |
17,779,753 13.100% |
2,944,538 (+19.85%) |
Filing History |
| 2023-09-19 5:25 pm Sale |
2023-09-15 | 13D | Cytek Biosciences, Inc. CTKB |
RA Capital Management, L.P. | 6,809,404 4.990% |
-6,329,923 (-48.18%) |
Filing History |
| 2023-05-05 11:52 am Purchase |
2023-04-30 | 13G | Cytek Biosciences, Inc. CTKB |
BLACKROCK INC BLK |
14,835,215 10.900% |
6,467,608 (+77.29%) |
Filing History |
| 2023-02-14 4:09 pm Sale |
2022-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
HHLR Advisors, Ltd. | 8,684,530 6.400% |
-72,500 (-0.83%) |
Filing History |
| 2023-02-09 11:16 am Purchase |
2022-12-30 | 13G | Cytek Biosciences, Inc. CTKB |
The Vanguard Group | 7,771,067 5.760% |
7,771,067 (New Position) |
Filing History |
| 2023-02-03 12:10 pm Purchase |
2022-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
BLACKROCK INC BLK |
8,367,607 6.200% |
8,367,607 (New Position) |
Filing History |
| 2022-08-03 5:26 pm Sale |
2022-08-03 | 13G | Cytek Biosciences, Inc. CTKB |
3E Bioventures Capital L.P. | 5,684,615 4.230% |
-4,002,250 (-41.32%) |
Filing History |
| 2022-03-14 5:04 pm Purchase |
2022-03-10 | 13D | Cytek Biosciences, Inc. CTKB |
RA Capital Management, L.P. | 13,139,327 9.800% |
2,057,164 (+18.56%) |
Filing History |
| 2022-02-28 5:29 pm Purchase |
2022-02-28 | 13D | Cytek Biosciences, Inc. CTKB |
RA Capital Management, L.P. | 11,082,163 8.300% |
1,475,135 (+15.35%) |
Filing History |
| 2022-02-16 6:27 pm Purchase |
2021-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
3E Bioventures Capital L.P. | 9,686,865 7.240% |
9,686,865 (New Position) |
Filing History |